BioNTech SE (LON:0A3M)

Market Cap	22.76B
Revenue (ttm)	2.53B
Net Income (ttm)	-388.53M
Shares Out	n/a
EPS (ttm)	-1.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,002
Average Volume	3,132
Open	119.55
Previous Close	120.70
Day's Range	118.66 - 124.34
52-Week Range	59.62 - 104.32
Beta	0.18
RSI	52.34
Earnings Date	Mar 21, 2025

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 6,133
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3M

Financial Performance

In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.

Financial numbers in EUR